A self-assembling peptide hydrogel that serves as both a vaccine and a CAR-T cell reservoir improved tumor targeting, CAR-T persistence, and triggered both innate and adaptive immune responses against HER2-positive solid tumors in mice.
Central memory T cells inducedThe peptide hydrogel-CAR-T system generated central memory T cells in systemic immune tissues — directly solving the persistence problem that has limited CAR-T therapy in solid tumors.
What the researchers found
The supramolecular peptide epitope vaccine encapsulated with CAR-T cells (SPEV-CAR-T) achieved multiple improvements over standard CAR-T therapy:
- The peptide hydrogel scaffold promoted CAR-T cell proliferation, cytotoxic activity, and lymphocyte subpopulation transformation (from effector to memory phenotypes)
- Complementary peptide epitopes from different extracellular domains of HER2 improved tumor antigen spreading and targeting efficiency
- Sustained release from the hydrogel maintained both vaccine and CAR-T cell delivery over time
- The system induced endogenous humoral and cellular immune responses alongside the exogenous CAR-T response
- Critically, SPEV-CAR-T generated central memory T cells in systemic immune tissues — directly addressing the poor persistence problem of CAR-T therapy
- Superior anti-tumor effects were demonstrated in an in vivo mouse model of solid tumors
Why it matters
CAR-T therapy has transformed treatment for blood cancers like leukemia and lymphoma, but solid tumors represent over 90% of all cancers and remain largely resistant to CAR-T. The two biggest challenges — limited CAR-T persistence and the immunosuppressive tumor microenvironment — are both addressed by this peptide hydrogel system. By combining a vaccine that activates the body's own immune system with engineered CAR-T cells in a single sustained-release platform, this approach creates a more comprehensive and durable anti-tumor immune response.
How the study worked
Researchers designed a self-assembling peptide that forms nanofiber scaffolds through non-covalent interactions of amphiphilic amino acids and ion stabilizers. Complementary peptide vaccine epitopes and CAR-T target sites were derived from different extracellular domains of HER2. The hydrogel was loaded with both the peptide epitope vaccine and CAR-T cells. In vitro experiments assessed CAR-T cell proliferation, cytotoxicity, and phenotype changes within the hydrogel. In vivo experiments in tumor-bearing mice evaluated anti-tumor efficacy, immune response induction (humoral and cellular), and central memory T cell generation in systemic immune tissues.
What this study cannot tell us
All experiments were conducted in mouse tumor models, which may not accurately predict human immune responses or solid tumor behavior. The HER2-specific system would only apply to HER2-positive cancers. Manufacturing complexity of combining a peptide hydrogel vaccine with live CAR-T cells presents significant clinical translation challenges. Long-term safety of sustained peptide hydrogel release at tumor sites is unknown. The immune response in immunodeficient tumor-bearing mice may differ substantially from immunocompetent cancer patients. Specific tumor sizes, survival curves, and quantitative immune metrics were not detailed in the abstract.
How to read the evidence
This is a preclinical proof-of-concept study demonstrating a novel biomaterial-immunotherapy combination in mouse tumor models. While the approach is innovative and the results are promising, all findings are in animal models and significant translation challenges remain.
When this study was published
Published in 2025, this is a very current study at the intersection of peptide biomaterials and cancer immunotherapy — two rapidly advancing fields.
The bigger picture
This study represents the convergence of three major cancer immunotherapy strategies: CAR-T cell engineering, peptide-based cancer vaccines, and biomaterial-assisted immune modulation. Self-assembling peptide hydrogels are uniquely suited for this application because they are biocompatible, injectable, and can be precisely engineered to display specific epitopes. The concept of using a single biomaterial to coordinate both active (vaccine) and passive (CAR-T) immunity is novel and could transform how immunotherapy is delivered for solid tumors.
Questions still open
- Can this peptide hydrogel-CAR-T platform be adapted to target other solid tumor antigens beyond HER2?
- How long does the hydrogel maintain its structural integrity and sustained release function at the tumor site?
- Would this approach work in combination with immune checkpoint inhibitors for enhanced anti-tumor immunity?
Common questions
What is CAR-T therapy and why doesn't it work well against solid tumors?
How does the peptide hydrogel help fight cancer?
Read the original research
Supramolecular peptide hydrogel epitope vaccine functionalized with CAR-T cells for the treatment of solid tumors.
Materials today. Bio, 31, 101517
Citation
Yang, Pengxiang; Yao, Xiaomin; Tian, Xue; Wang, Yuehan; Gong, Leilei; Yang, Yumin; Jie, Jing. (2025). Supramolecular peptide hydrogel epitope vaccine functionalized with CAR-T cells for the treatment of solid tumors.. Materials today. Bio, 31, 101517. https://doi.org/10.1016/j.mtbio.2025.101517